Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625217 · ClinicalTrials.gov registry record · NA
Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT05625217 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 7 participants.
The verdict
NCT05625217, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The overall goal of this research study is to understand how 18F-fluorodeoxyglucose (FDG), a radioactive sugar behaves in head and neck cancer (HNC) and inflammation immediately following injection and at many hours post-injection, with the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER).
Interventions
- DIAGNOSTIC_TEST Total Body PET/CT Imagin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2024-11-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05625217
The ClinicalTrials.gov registry entry for NCT05625217 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Total Body PET/CT Imagin is the first listed.
NCT05625217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05625217 about?
NCT05625217 is a clinical study titled "Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer". The overall goal of this research study is to understand how 18F-fluorodeoxyglucose (FDG), a radioactive sugar behaves in head and neck cancer (HNC) and inflammation immediately following injection and at many hours post-injection, with the world's first total-body positron emission tomography (PET)...
What is the current status of trial NCT05625217?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2023-02-27. Estimated completion is 2024-11-20.
What interventions are being tested in trial NCT05625217?
The interventions under investigation include: Total Body PET/CT Imagin (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05625217?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.